Similar articles

• Loss of mismatched HLA in leukemia after stem-cell transplantation.

  Vago L, Perna SK, Zanussi M, Mazzi B, Barlassina C, Stanghellini MT, Perrelli NF, Cosentino C, Torri F, Angius A, Forno B, Casucci M, Bernardi M, Peccatori J, Corti C, Bondanza A, Ferrari M, Rossini S, Roncarolo MG, Bordignon C, Bonini C, Ciceri F, Fleischhauer K. Vago L, et al. N Engl J Med. 2009 Jul 30;361(5):478-88. doi: 10.1056/NEJMoa0811036. N Engl J Med. 2009. PMID: 19641204
• Different mechanisms causing loss of mismatched human leukocyte antigens in relapsing t(6;11)(q27;q23) acute myeloid leukemia after haploidentical transplantation.

  Tamaki H, Fujioka T, Ikegame K, Yoshihara S, Kaida K, Taniguchi K, Kato R, Tokugawa T, Nakata J, Inoue T, Yano A, Eguchi R, Okada M, Maruya E, Saji H, Ogawa H. Tamaki H, et al. Eur J Haematol. 2012 Dec;89(6):497-500. doi: 10.1111/ejh.12017. Epub 2012 Oct 26. Eur J Haematol. 2012. PMID: 23033942
• Reduced-intensity stem cell transplantation from an HLA-identical sibling donor in patients with myeloid malignancies.

  Hamaki T, Kami M, Kim SW, Onishi Y, Kishi Y, Murashige N, Hori A, Kojima R, Sakiyama M, Imataki O, Heike Y, Tanosaki R, Masuo S, Miyakoshi S, Taniguchi S, Tobinai K, Takaue Y. Hamaki T, et al. Bone Marrow Transplant. 2004 May;33(9):891-900. doi: 10.1038/sj.bmt.1704477. Bone Marrow Transplant. 2004. PMID: 15048142 Clinical Trial.
• Allogeneic hematopoietic stem cell transplantation (HSCT) for high-risk acute myeloid leukemia (AML)/myelodysplastic syndrome (MDS): how can we improve outcomes in the near future?

  Phillips GL. Phillips GL. Leuk Res. 2012 Dec;36(12):1490-5. doi: 10.1016/j.leukres.2012.08.004. Epub 2012 Sep 3. Leuk Res. 2012. PMID: 22954609 Review.
• Genomic loss of mismatched human leukocyte antigen and leukemia immune escape from haploidentical graft-versus-leukemia.

  Vago L, Toffalori C, Ciceri F, Fleischhauer K. Vago L, et al. Semin Oncol. 2012 Dec;39(6):707-15. doi: 10.1053/j.seminoncol.2012.09.009. Semin Oncol. 2012. PMID: 23206847 Review.